期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人胰升糖素样肽-1类似物利拉鲁有为减轻2型糖尿病患者体重及减少低血糖风险的作用 被引量：8

原文传递
导出
摘要 当前2型糖尿病治疗手段面临血糖控制不理想,现有方案很难从根本上改善β细胞功能、降低药物可引起体重增加和低血糖等不良作用,患者同时丰收在肥胖和高血压等心脑血管病高危因素等"多种挑战"。在这种背景下,人们普遍开始关注新型肠促胰素类药物。人胰升糖素样肽-1类似物利拉鲁肽具有促进胰岛素的合成和分泌、保护β细胞减少低血糖、减少食物摄取、延缓胃排空、减轻体重、降低收缩压和改善心脑血管疾病危险因素等生理作用。
作者 张存志 秦恒斌 邸力强 曹瑞芳
机构地区 河北省赵县糖尿病研究所
出处 《实用糖尿病杂志》 2012年第2期43-44,共2页 Journal of Practical Diabetology
关键词 利拉鲁肽 2型糖尿病 体重 低血糖 减轻
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

二级参考文献36

  • 1潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量：193
  • 2Orskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diahetologia, 1992,35:701-711.
  • 3Agerso H, Jensen LB, Elbrond B, et al. The pharmacokineties, pharmacodynamics, safety and tolerability of NN2211 , a new longacting GLP-1 derivative, in healthy men. Diabelologia, 2002,45 :195-202.
  • 4Damholt B, Golor G, Wiefich W, et al. An open-label, parallel group study investigating the effecls of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutlde. J Clin Pharmacol,2006,46:635-641.
  • 5Garber A, Henry R, Rather R, et al. Significantly better glycemic eontrol and weight reduclion with liraglutide, a once-daily human GLP-1 analog, compared with glimepiride: All as monolherapy in type 2 diabeles. ADA 68th Scientific Sessions. Diabeles,2008 ,57 ( Suppl 1 ) :7-LB.
  • 6Nauck MA. Frid A. Hermansen K, el al. Liraglutide, a oncedaily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight eompared with glimepiride when added to metfonnin. ADA 68th Scientific Sessions. Diabetes ,2008,57( Suppl 1) :504-P.
  • 7Marre M, Shaw J, Brandle M, et al. Liraglutide,a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers signifi cantly belier glycemic conlrol and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. ADA 68th Scientific Sessions. Diabeles, 2008,57 ( Suppl 1 ) : 13-OR.
  • 8Russell-Jones D, Vaag A, Schmitz O, et al. Significanlly better glycemie control and weight reduction with liraglutide,a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. ADA 68th Scientific Sessions. Diabetes, 2008,57 (Suppl 1 ) :536 P.
  • 9Nauck M, Brandle M, Vaag A ,et al. The once-daily human GLP-I analog liraglulide substantially reduces HbAlc in sabjecls with type 2 diabetes,irrespective of HbA1 c at baseline. ADA 68th Scientific Sessions. Diabetes, 2008,57 (Suppl 1) : 2148-PO.
  • 10Groop LC. Etiology of non-insulin-dependent diabetes mellitus. In : Leslie, RDG. Molecular pathogenesls of diabetes mellitus. Karger, 1997,22 : 131-156.

共引文献60

同被引文献58

  • 1胡仁明,李洪超.胰高血糖素样多肽-1类药治疗2型糖尿病的复合终点评价[J].中华糖尿病杂志,2010,2(4). 被引量：16
  • 2Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26 : sulpho- nylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study ( UKPDS ) Group E J]. Diabetes Med, 1998,15:297-303.
  • 3Garber A, Henry RR, Rather R, et al. Liraglutide, a once-daily human glucagon like peptide 1 analogue, provides sustained improve, ments in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes [ J ]. Diabetes Obes Metab ,2011,13 : 348.
  • 4中华医学会糖尿病学分会护理及糖尿病教育学组.中国糖尿病护理及教育指南[M].2009:13-17.
  • 5Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabe- tes mellitus type 2 [ J ]. Am J Physiol, 1999,276 ( 5 Pt 2 ) : R1541-R1544.
  • 6Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal:effects of exogenous glucagon-like peptide-1 ( GLP-1 ) -( 7-36 ) amide in type 2 (noninsulin-dependent) diabetic patients [ J ]. J Clin Endocrinol Metab, 1996,81 ( 1 ) :327-332.
  • 7Matthews D. Liraglutide improves 13 cell function as assessed by HOMA - B and proinsulin : insulin ratiometa analysis of six clinical trials[ J]. Diabetes ,2010,59(s) : 1513.
  • 8Russell Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes [ J ]. Int J Clin Pract,2010,64.
  • 9全国糖尿病研究协作组调查研究组.全国14省市30万人口中糖尿病调查报告[J].中华内科杂志,1981,20(11):678.
  • 10Garber A, Henry RR, Rather R, et al. Liraglutide, a once- daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2011, 13(4):348-356.

引证文献8

二级引证文献33

实用糖尿病杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部